DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2242107/are-investors-undervaluing-collegium-pharmaceutical-coll-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2242107 Mar 18, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. 0

https://www.zacks.com/stock/news/2236651/here-s-why-you-should-invest-in-aldeyra-aldx-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2236651 Mar 06, 2024 - Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move. 0

https://www.zacks.com/stock/news/2234845/are-you-looking-for-a-top-momentum-pick-why-collegium-pharmaceutical-coll-is-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2234845 Mar 01, 2024 - Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out. 0

https://www.zacks.com/stock/news/2230573/here-s-what-key-metrics-tell-us-about-collegium-pharmaceutical-coll-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2230573 Feb 22, 2024 - The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2227991/analysts-estimate-recursion-pharmaceuticals-rxrx-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2227991 Feb 19, 2024 - Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2215195/why-collegium-pharmaceutical-coll-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2215195 Jan 24, 2024 - Collegium Pharmaceutical (COLL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. 0

https://www.zacks.com/stock/news/2205736/collegium-coll-shares-rise-on-financial-outlook-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205736 Jan 04, 2024 - Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same. 0